Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047756 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2638022 | 0.94 | KMT2A (0.35) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12782269 | 0.91 | MAPT (0.35) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL15047710 | 0.91 | MAPT (0.35) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1314947 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL11963290 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1317324 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1314942 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL11963399 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| Deferitazole SCHEMBL17209568 | 0.91 | KMT2A (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323534-A1 | USES OF 3'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2013090766-A1 | USES OF 3'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013086312-A1 | ORAL FORMULATIONS FOR TREATING METAL OVERLOAD | FERROKIN BIOSCIENCES, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323534-A1 | USES OF 3'-DESFERRITHIOCIN ANALOGS | TFRC, AIFM2, FTH1 | SMN1; SMN2 511/4885MEN1 1816/4885KMT2A 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.